FDA Approves Mannkind's At-Home Treatment Option for Heart Failure or Kidney Disease
Benzinga
公開日時: Jul 25, 2026, 03:06 AM GMT+9
Sentiment Analysis
FDA Approves Mannkind's At-Home Treatment Option for Heart Failure or Kidney Disease
The FDA has approved Furoscix ReadyFlow, a furosemide injection designed to treat edema (swelling caused by excess fluid trapped in the body’s tissue) in adults with heart failure or chronic kidney disease .
The product is notable for being the first autoinjector delivering IV-equivalent exposure, potentially allowing for quicker symptom relief and reducing the need for emergency interventions.
Furoscix ReadyFlow provides a full 80 mg/mL dose in a simple, patient- friendly format administered in under 10 seconds.
Heart failure affects approximately 6.7 million adults in the United States and is projected to increase to more than 8 million by 2030.
Source: Benzinga
個別の投資に関する推奨やアドバイスを提供することを意図しておりません。ここで述べられている意見や見解は、あくまでも各記事の個人的見解です。